Pyxis Stock Based Compensation from 2010 to 2024
| PYXS Stock | USD 2.01 0.18 9.84% |
Stock Based Compensation | First Reported 2010-12-31 | Previous Quarter 16.9 M | Current Value 8.6 M | Quarterly Volatility 6 M |
Check Pyxis Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pyxis Oncology's main balance sheet or income statement drivers, such as Net Interest Income of 7.3 M, Interest Income of 7.3 M or Depreciation And Amortization of 2.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.6. Pyxis financial statements analysis is a perfect complement when working with Pyxis Oncology Valuation or Volatility modules.
Pyxis | Stock Based Compensation |
Latest Pyxis Oncology's Stock Based Compensation Growth Pattern
Below is the plot of the Stock Based Compensation of Pyxis Oncology over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Pyxis Oncology's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pyxis Oncology's overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation | 10 Years Trend |
|
Stock Based Compensation |
| Timeline |
Pyxis Stock Based Compensation Regression Statistics
| Arithmetic Mean | 3,206,937 | |
| Geometric Mean | 142,051 | |
| Coefficient Of Variation | 185.86 | |
| Mean Deviation | 4,660,308 | |
| Median | 28,000 | |
| Standard Deviation | 5,960,350 | |
| Sample Variance | 35.5T | |
| Range | 16.9M | |
| R-Value | 0.71 | |
| Mean Square Error | 18.8T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 950,341 | |
| Total Sum of Squares | 497.4T |
Pyxis Stock Based Compensation History
Other Fundumenentals of Pyxis Oncology
Pyxis Oncology Stock Based Compensation component correlations
Click cells to compare fundamentals
About Pyxis Oncology Financial Statements
Pyxis Oncology shareholders use historical fundamental indicators, such as Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although Pyxis Oncology investors may analyze each financial statement separately, they are all interrelated. The changes in Pyxis Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pyxis Oncology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation | 16.9 M | 8.6 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.